JWJiawei Wang

Jiawei Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiawei Wang has a total of 182 co-authors. Here are the top co-authors by number of shared publications:

  • Lei Liu

    Department of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China

    13 shared publications
  • Yanjun Guo

    Department of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China

    9 shared publications
  • Hanqiu Jiang

    Department of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China

    7 shared publications
  • Feifei Dai

    Neurology Department of Beijing Tongren Hospital, Capital Medical University, Beijing, China

    5 shared publications
  • Lin Li

    Department of Neurology, Beijing Tongren Hospital, Capital Medical University, 100000 Beijing, China

    5 shared publications
  • Shilei Cui

    Neurology Department of Beijing Tongren Hospital, Capital Medical University, Beijing, China

    5 shared publications

Latest Publications

  • Open Access

    Oculomotor phenotypes and longitudinal video-oculography dynamics in anti-GAD65 antibody–associated neurological syndromes: a case series and literature review

    by Feifei Dai, Shilei Cui, Yanjun Guo, Jiawei Wang

    Background: Anti–glutamic acid decarboxylase (GAD) antibody–associated neurological syndromes encompass a heterogeneous group of immune-mediated disorders in which ocular involvement is increasingly recognized but remains insufficiently characterized. Data on clinical features, neuroimaging, and longitudinal ocular motor findings are limited. Methods: We retrospectively reviewed four patients diagnosed with anti-GAD antibody–associated neurological syndromes presenting with ocular manifestations at our center between 2019 and 2025. Clinical features, ocular motor findings, laboratory and neuroimaging results, treatment, and outcomes were collected. Longitudinal video-oculography (VOG) was analyzed in one patient. A literature review was performed to summarize reported ocular and vestibulo-ocular abnormalities. Results: All four patients (2 males, 2 females; onset age 53–68 years) exhibited ocular symptoms, three presented with ocular symptoms early in the disease course; however, in one case (Case 4), the temporal association between the initial ocular symptom and the final diagnosis remained uncertain. Diplopia, nystagmus, and ptosis were the predominant findings. Early brain and orbital Magnetic Resonance Imaging (MRI) were unremarkable, while cerebellar atrophy developed in one patient during relapse. All patients were positive for serum anti-GAD65 antibodies; one also had anti-titin antibodies with elevated creatine kinase(CK). VOG in one patient demonstrated worsening saccadic velocity and pursuit gain during relapse, consistent with cerebellar dysfunction. Literature review of 61 articles showed that diplopia and nystagmus were the most frequently reported features, with characteristic vestibulo-ocular abnormalities including multistep saccades and square-wave oscillations. Based on clinical and literature findings, we further identified recurrent oculomotor patterns across cases. Conclusions: Ocular symptoms may represent early clinical features of anti-GAD antibody–associated neurological syndromes, although the temporal relationship may vary across patients and should be interpreted with caution in atypical cases. Downbeat nystagmus may serve as an early marker of cerebellar involvement. Longitudinal VOG provides objective insights into disease evolution. Importantly, we propose a structured oculomotor phenotype framework and highlight longitudinal VOG as a tool for tracking dynamic cerebellar dysfunction, which may facilitate earlier recognition and monitoring of disease progression.


  • Acetylcarnitine in cerebrospinal fluid and blood as a protective factor for neuromyelitis optica spectrum disorders: a mendelian randomization study

    by Zhuxiao Xie, Feng Gai, Lei Liu, Yanjun Guo, Hanqiu Jiang, Weijiao Zhang, Jiawei Wang

    Background Neuromyelitis Optica Spectrum Disorders (NMOSD) are a group of diseases that can cause vision loss and paralysis. Some patients with refractory NMOSD continue to experience relapses or even disability after existing treatments, so it is crucial to further investigate the targets for precision therapy. The link between cerebrospinal fluid (CSF) and blood metabolites and the pathogenesis of NMOSD remains underexplored. Methods We conducted a two-sample mendelian randomization (MR) study. Instrumental variables related to 338 CSF metabolites and 486 blood metabolites were extracted from genome-wide association (GWAS) data involved European individuals. A series of sensitivity analyses were applied, including the Cochran Q test, MR-Egger intercept test, MR-PRESSO, and leave-one-out method. Finally, we conducted functional enrichment analysis within MetaboAnalyst 5.0. Results We identified 20 CSF metabolites and 11 blood metabolites indicated causality with NMOSD. We observed a protective effect of acetylcarnitine within NMOSD, both in CSF (OR = 0.47, P value = 7.088 × 10−6) and blood (OR = 0.02, P value = 0.017). Moreover, functional enrichment analysis identified a set of metabolic pathways potential related to the pathogenesis of NMOSD. Conclusion This is the first MR analysis to investigate the causality of CSF and blood metabolites in NMOSD. Acetylcarnitine was a protective factor for NMOSD, with a promising prospect for the treatment of refractory NMOSD. Several other key CSF and blood metabolites could also serve as the candidate molecules for exploring mechanisms and potential drug targets.


  • Open Access

    Effects of coronavirus disease 2019 in patients with optic neuritis: a single-centre retrospective cohort study

    by Rong Yan, Yanjun Guo, Chao Meng, Xiuyun Kong, Jiawei Wang

    Background: The relationship between coronavirus disease 2019 (COVID-19) and optic neuritis (ON) remains unclear, with limited evidence on its clinical features and outcomes. This study aimed to investigate the impact of COVID-19 on ON subtypes and prognosis. Methods: We conducted a single-centre retrospective cohort study, comparing acute ON patients with and without recent COVID-19 infection during the omicron wave (December 2022 to January 2023). A historical control group from the pre-COVID-19 era was included for comparison. Results: A total of 55 ON patients were included, of whom 12 had recent COVID-19 infection. COVID-19-associated ON showed a higher incidence of acute disseminated encephalomyelitis-associated ON (ADEM-ON, 25% vs. 0%) and a lower rate of aquaporin-4 antibody-associated ON (AQP4-ON, 0% vs. 31.4%). These patients presented more frequently with eye pain (75%) and respiratory symptoms (60%). At onset, 66.7% experienced severe visual loss (mean logMAR 1.10 ± 0.71), but most (83.3%) achieved good visual recovery (mean logMAR 0.08 ± 0.44) after immunotherapy. Only one relapse was observed during follow-up. Conclusions: COVID-19 may trigger distinct autoimmune processes in ON, particularly increasing ADEM-ON prevalence. Despite initial severe vision loss, outcomes are generally favourable with timely treatment. These findings expand understanding of neuro-ophthalmic complications related to COVID-19.


  • Open Access

    Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER

    by Xiaomeng Di, Xiaohong Shi, Feng Gai, Jiawei Wang

    Background: Immune checkpoint inhibitor (ICI)-associated neurological immune-related adverse events (NAEs) are rare but serious side effects, of which autoimmune encephalitis (AIE) is a potentially fatal central nervous system disorder requiring more attention.Methods: We performed a retrospective disproportionality analysis of NAE reports in the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Event Reporting Database (JADER) from 2004 to 2024, utilizing reporting odds ratio (ROR), proportional reporting ratio (PRR), the Bayesian confidence propagation neural network BCPNN, and the multi-item gamma Poisson shrinker (MGPS) for signal detection.Results: In total, 3,999 reports of ICI-associated NAEs were identified from the FAERS database, of which 1,998 reports were AIE. 1,558,251 reports of AEs were collected from the JADER database, which contained 890 AIE reports. ICIs, including pembrolizumab, nivolumab, atezolizumab, ipilimumab, and durvalumab, were identified among the top 30 agents in both databases, demonstrating significant signals across all 4 algorithms. Except for noninfectious myelitis, acute disseminated encephalomyelitis, and multiple sclerosis, positive signals were detected in all other preferred terms (PTs). These NAEs accounted for 23.7% of total mortality, with myasthenia gravis (MG) exhibiting the highest mortality rate at 30.63%. Specific PTs, such as aseptic meningitis, AIE, chronic inflammatory demyelinating polyradiculoneuropathy, Guillain-Barré syndrome, MG, myelitis, and immune-related myopathy, were associated with the severity of outcomes, showing significant statistical differences between severe and non-severe cases (p < 0.05).Conclusion: Our study found a notable correlation between ICIs and AIE and other specific NAEs, highlighting the demographic characteristics, time to onset, and disease severity of ICI-induced NAEs, thereby facilitating the timely recognition and treatment of these ICI therapy-related complications.


  • Open Access

    Exosomal miR-432-5p, miR-4433b-5p, and miR-599: Biomarkers for Monitoring the Severity of Anti-N-methyl-D-aspartate Receptor Encephalitis

    by Zhuxiao Xie, Lei Liu, Yanjun Guo, Hanqiu Jiang, Lin Li, Zhixin Qiao, Jiawei Wang

    Background: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a rare disease with a high disability rate, characterized by acute-to-subacute psychiatric and/or neurological symptoms. Continuous intrathecal antibody synthesis does not correlate with the active phase of encephalitis and antibody titers do not directly reflect the severity of the condition. Currently, there is a lack of biomarkers for disease monitoring. This study focuses on finding novel peripheral blood biomarkers that can accurately monitor the severity of anti-NMDAR encephalitis. Methods: Peripheral blood samples were collected from patients with anti-NMDAR encephalitis, including those with acute-phase (autoimmune encephalitis (AE)-a group) and stable-phase (AE-s group) autoimmune encephalitis. Healthy individuals were included as controls (HC group). We isolated exosomal microRNAs (miRNAs) from the samples and screened differentially expressed miRNAs through next-generation sequencing. The sequencing results were validated using quantitative real-time qPCR (RT-qPCR). Furthermore, we conducted a correlation analysis between the expression levels of the screened miRNAs and clinical severity. Finally, we performed functional pathway analysis to explore the underlying mechanisms in anti-NMDAR encephalitis. Results: We found that exosomal miR-432-5p, miR-4433b-5p, and miR-599 exhibited significant differences between patients with anti-NMDAR encephalitis and healthy controls, as well as at various phases of the disease. The expression of miR-432-5p and miR-4433b-5p were negatively correlated with clinical severity. We further identified that key pathways including rhythmic processes and glutamatergic signaling play significant roles in the pathogenesis of anti-NMDAR encephalitis. Conclusions: Our research indicated that exosomal miR-432-5p, miR-4433b-5p, and miR-599 were correlated with the severity of anti-NMDAR encephalitis and can serve as potential biomarkers for disease monitoring. Moreover, the key functional pathways predicted by these miRNAs may play crucial roles in disease progression.


  • Open Access

    Prediction model for severe autoimmune encephalitis: a tool for risk assessment and individualized treatment guidance

    by Zhuxiao Xie, Jingxiao Zhang, Lei Liu, Enyu Hu, Jiawei Wang

    Background: Severe autoimmune encephalitis (AE) can cause significant neurological deficits, status epilepticus, status dystonicus, and even death, which can be life-threatening to patients. Accurate risk stratification for severe AE progression is critical for optimizing therapeutic strategies. The comprehensive prediction models for severe AE based on routine clinical data and laboratory indicators remain lacking.Objective: To develop and validate a prediction model for severe AE to optimize individualized treatment.Methods: We collected clinical data and laboratory examination results from 207 patients with confirmed AE. The study population was divided into development and validation cohort. A prediction model for severe AE was constructed using a nomogram and was rigorously validated both internally and externally. Severe AE was defined as modified Rankin Scale (mRS) > 2 and Clinical Assessment Scale for Encephalitis (CASE) > 4.Results: The variables ultimately included in the nomogram for the severe AE predictive model were age, psychiatric and/or behavioral abnormalities, seizures, decreased level of consciousness, cognitive impairment, involuntary movements, autonomic dysfunction, and increased intrathecal IgG synthesis rate. It demonstrated excellent discriminative capacity and calibration through internal-external validation.Conclusion: The prediction model has highly feasibility in clinical practice, and holds promise as an important tool for risk assessment and guiding individualized treatment in patients with AE.


  • Genetic Insights into Therapeutic Targets for Neuromyelitis Optica Spectrum Disorders: A Mendelian Randomization Study

    by Yangyue Cao, Jingxiao Zhang, Jiawei Wang

    Neuromyelitis optica spectrum disorder (NMOSD) is a severe central nervous system disease primarily characterized by optic neuritis and myelitis, which can result in vision loss and limb paralysis. Current treatment options are limited in their ability to prevent relapses and mitigate disease progression, underscoring the urgent need for new drug targets to develop more effective therapies. The objective of this study is to identify potential drug targets associated with a reduced risk of NMOSD attacks or relapses through Mendelian randomization (MR) analysis, thereby addressing the limitations of existing treatment methods and providing better clinical options for patients. To identify therapeutic targets for NMOSD, a MR analysis was conducted. The cis-expression quantitative trait loci (cis-eQTL, exposure) data were sourced from the eQTLGen consortium, which included a sample size of 31,684. NMOSD (outcome) summary data were obtained from two of the largest independent cohorts: one cohort consisted of 86 NMOSD cases and 460 controls derived from whole-genome sequencing data, while the other cohort included 129 NMOSD patients and 784 controls. We performed a two-sample MR analysis to evaluate the association between single nucleotide polymorphisms (SNPs) and copy number variations with NMOSD. The MR analysis utilized the inverse variance weighted (IVW) method, supplemented by MR-Egger, weighted median, simple mode, and weighted mode methods. Sensitivity analyses were conducted to assess the presence of horizontal pleiotropy and heterogeneity. Colocalization analysis was employed to test whether NMOSD risk and gene expression are driven by common SNPs. Additionally, a phenome-wide association study (PheWAS) was performed to detect disease outcomes associated with NEU1. Supplementary analyses included single-nucleus RNA sequencing (snRNA-seq) data analysis, protein–protein interaction (PPI) networks, and drug feasibility assessments to prioritize potential therapeutic targets. Two drug targets, COL4A1 and NEU1, demonstrated significant MR results in two independent datasets. Notably, NEU1 showed substantial evidence of colocalization with NMOSD. Additionally, apart from the association between NEU1 and NMOSD, no other associations were observed between gene-proxied NEU1 inhibition and the increased risk of other NMOSD-related diseases. This study supports the potential of targeting NEU1 for drug inhibition to reduce the risk of NMOSD. Further preclinical research and drug development are warranted to validate the efficacy and safety of NEU1 as a therapeutic target and to explore its potential in NMOSD treatment.


  • Open Access

    Simulated microgravity‐induced dysregulation of cerebrospinal fluid immune homeostasis by disrupting the blood–cerebrospinal fluid barrier

    by Jing Yang, Yaoyuan Cui, Juan Zhao, Shiyi Tang, Anqing Wang, Junxiao Wang, Yu Chen, Jilong Luo, Guan Wang, Junhao Yan, et al.

    Background: The blood–cerebrospinal fluid barrier (BCSFB) comprises the choroid plexus epithelia. It is important for brain development, maintenance, function, and especially for maintaining immune homeostasis in the cerebrospinal fluid (CSF). Although previous studies have shown that the peripheral immune function of the body is impaired upon exposure to microgravity, no studies have reported changes in immune cells and cytokines in the CSF that reflect neuroimmune status. The purpose of this study is to investigate the alterations in cerebrospinal fluid (CSF) immune homeostasis induced by microgravity and its mechanisms. This research is expected to provide basic data for brain protection of astronauts during spaceflight.Methods: The proportions of immune cells in the CSF and peripheral blood (PB) of SMG rats were analyzed using flow cytometry. Immune function was evaluated by measuring cytokine concentrations using the Luminex method. The histomorphology and ultrastructure of the choroid plexus epithelia were determined. The concentrations of intercellular junction proteins in choroid plexus epithelial cells, including vascular endothelial‐cadherin (VE‐cadherin), zonula occludens 1 (ZO‐1), Claudin‐1 and occludin, were detected using western blotting and immunofluorescence staining to characterize BCSFB injury.Results: We found that SMG caused significant changes in the proportion of CD4 and CD8 T cells in the CSF and a significant increase in the levels of cytokines (GRO/KC, IL‐18, MCP‐1, and RANTES). In the PB, there was a significant decrease in the proportion of T cells and NKT cells and a significant increase in cytokine levels (GRO/KC, IL‐18, MCP‐1, and TNF‐α). Additionally, we observed that the trends in immune markers in the PB and CSF were synchronized within specific SMG durations, suggesting that longer SMG periods (≥21 days) have a more pronounced impact on immune markers. Furthermore, 21d‐SMG resulted in ultrastructural disruption and downregulated expression of intercellular junction proteins in rat choroid plexus epithelial cells.Conclusions: We found that SMG disrupts the BCSFB and affects the CSF immune homeostasis. This study provides new insights into the health protection of astronauts during spaceflight.


  • Open Access

    Development of a short-term prognostic model for anti-N-methyl-D-aspartate receptor encephalitis in Chinese patients

    by Jingxiao Zhang, Yatong Li, Lei Liu, Feifei Dai, Yujing Peng, Qiuying Ma, Lin Li, Yu Hong, Aihua Liu, Xinghu Zhang, et al.

    Background: Recognizing the predictors of poor short-term prognosis after first-line immunotherapy in patients with anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is essential for individualized treatment strategy. The objective of this study was to ascertain the factors that forecast short-term prognosis in patients with anti-NMDAR encephalitis, develop a prognostic prediction model, and authenticate its efficacy in an external validation cohort. Further, all patients were followed-up long-term to assess the factors of long-term outcome and relapses. Methods: A prospective enrollment of patients diagnosed with anti-NMDAR encephalitis was conducted across five clinical centers in China from June 2014 to Mar 2022. The enrolled patients were divided into the derivation and validation sets based on enrollment time. The short-term prognostic model was visualized using a nomogram. Further, all patients were followed-up long-term to assess the factors of long-term outcome. Results: This study found that poor short-term prognosis was a risk factor for poor long-term outcome (6-month prognosis, OR 29.792, 95%CI 6.507-136.398, p < 0.001; 12-month prognosis, OR 15.756, 95%CI 3.384–73.075, p < 0.001; 24-month prognosis, OR 5.500, 95%CI 1.045–28.955, p = 0.044). Abnormal behavior or cognitive dysfunction (OR 8.57, 95%CI 1.48–49.79, p = 0.017), consciousness impairment (OR19.32, 95%CI 3.03-123.09, p = 0.002), autonomic dysfunction or central hypoventilation (OR 5.66, 95%CI 1.25–25.75, p = 0.025), CSF pleocytosis (OR 4.33, 95%CI 1.48–12.65, p = 0.007), abnormal EEG (OR 5.48, 95% CI 1.09–27.54, p = 0.039) were independent predictors for a poor short-term prognosis after first-line immunotherapy. A nomogram that incorporated those factors showed good discrimination and calibration abilities. The area under the curve (AUC) for the prognostic model were 0.866 (95%CI: 0.798–0.934) with a sensitivity of 0.761 and specificity of 0.869. Conclusion: We established and validated a prognostic model that can provide individual prediction of short-term prognosis after first-line immunotherapy for patients with anti-NMDAR encephalitis. This practical prognostic model may help neurologists to predict the short-term prognosis early and potentially assist in adjusting appropriate treatment timely.